IBRX
ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.48
+0.24%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 22.07x
- P/S forward
- 33.64x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -8.59x
- Price / sales
- 54.21x
- Price / cash flow
- -25.21x
Enterprise value
- Enterprise value
- $9.4B
- EV / sales
- 56.96x
- EV / EBITDA
- -10.63x
- EV / EBIT
- -37.51x
- Market cap
- $9.0B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026